Colon Cancer Clinical Trials
Colon cancer clinical trials provide patients with opportunities to access novel treatments before they are made available for use in other settings. Each trial is individualized based on a number of variables and overseen by a team of oncologists and research specialists. Generally speaking, these studies are performed to determine whether a new therapy is more effective than a standard one, what sort of side effects a treatment might produce, how well a therapy works with others or what type of patients are most likely to benefit from a new treatment.
The clinical trials program at Moffitt Cancer Center has provided countless patients with the ability to be among the first to benefit from new therapies as soon as they become available. It has also provided our oncologists with a better understanding of the condition in general, which we use to improve treatment for all patients.
Through past colon cancer clinical trials, researchers have determined:
- Which chemotherapy medications are most effective for the different types and stages of colon cancer
- How targeted therapies (medications that interfere with the growth of cancer cells while leaving healthy cells unaffected) can be used along with or in place of chemotherapy
- The most effective surgical techniques for removing a tumor from the delicate tissues of the colon
- The best ways to enhance long-term quality of life for colon cancer patients and survivors
- Ways to improve colon cancer screening and early detection processes
In recognition of our commitment to advancing colon cancer research and treatment strategies, Moffitt has been recognized as a Comprehensive Cancer Center by the National Cancer Institute. We are the only such center based in Florida.
If you are considering a clinical trial, our oncologists can help you find a study that meets your needs. For more information about the colon cancer clinical trials we are currently conducting, call 1-888-663-3488 or submit a new patient registration form online. No referral is required.